PIII vs. XGN, DCGO, KDLY, EUDA, CORBF, ATPC, QIPT, BMGL, SERA, and OPGN
Should you be buying P3 Health Partners stock or one of its competitors? The main competitors of P3 Health Partners include Exagen (XGN), DocGo (DCGO), Kindly MD (KDLY), EUDA Health (EUDA), Global Cord Blood (CORBF), Agape ATP (ATPC), Quipt Home Medical (QIPT), Basel Medical Group (BMGL), Sera Prognostics (SERA), and OpGen (OPGN). These companies are all part of the "healthcare" industry.
P3 Health Partners vs. Its Competitors
P3 Health Partners (NASDAQ:PIII) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, community ranking, valuation, risk, earnings, profitability, media sentiment and institutional ownership.
P3 Health Partners has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Exagen has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500.
P3 Health Partners presently has a consensus target price of $16.25, indicating a potential upside of 155.91%. Exagen has a consensus target price of $7.50, indicating a potential upside of 7.45%. Given P3 Health Partners' higher possible upside, equities research analysts clearly believe P3 Health Partners is more favorable than Exagen.
Exagen has lower revenue, but higher earnings than P3 Health Partners. Exagen is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.
In the previous week, Exagen had 2 more articles in the media than P3 Health Partners. MarketBeat recorded 4 mentions for Exagen and 2 mentions for P3 Health Partners. Exagen's average media sentiment score of 0.94 beat P3 Health Partners' score of 0.30 indicating that Exagen is being referred to more favorably in the news media.
7.8% of P3 Health Partners shares are owned by institutional investors. Comparatively, 75.3% of Exagen shares are owned by institutional investors. 17.8% of P3 Health Partners shares are owned by company insiders. Comparatively, 12.6% of Exagen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Exagen received 23 more outperform votes than P3 Health Partners when rated by MarketBeat users. Likewise, 62.22% of users gave Exagen an outperform vote while only 31.25% of users gave P3 Health Partners an outperform vote.
P3 Health Partners has a net margin of -6.95% compared to Exagen's net margin of -30.36%. P3 Health Partners' return on equity of -71.31% beat Exagen's return on equity.
Summary
Exagen beats P3 Health Partners on 12 of the 18 factors compared between the two stocks.
Get P3 Health Partners News Delivered to You Automatically
Sign up to receive the latest news and ratings for PIII and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PIII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
P3 Health Partners Competitors List
Related Companies and Tools
This page (NASDAQ:PIII) was last updated on 6/13/2025 by MarketBeat.com Staff
